Commerzbank Aktiengesellschaft FI lifted its stake in shares of Teva Pharmaceutical Industries by 116.2% in the 4th quarter. The institutional investor owned 71,908 shares of the company's stock after purchasing an additional 20,000 shares during the quarter.
Other institutional investors also recently made changes to their positions in the company. Fieldpoint Private Securities LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $171,000. Bank of Nova Scotia now owns 6,903 shares of the company's stock worth $229,000 after purchasing an additional 528 shares in the last quarter. WealthTrust Axiom LLC raised its position in shares of Teva Pharmaceutical Industries by 29.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Teva Pharmaceutical Industries by 1.6% in the fourth quarter. Menora Mivtachim Holdings LTD. lifted its stake in shares of Teva Pharmaceutical Industries by 377.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 198,178 shares of the company's stock worth $3,755,000 after purchasing an additional 3,100 shares during the period. Institutional investors own 49.99% of the company's stock.
In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total transaction of $99,384.00. Following the completion of the sale, the executive vice president now directly owns 44,517 shares of the company's stock, valued at approximately $876,094.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of equities analysts have weighed in on the stock.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated Teva Pharmaceutical Industries Limited (NYSE:TEVA) as Buy, 0 analysts given Outperform signal, 10 reported Hold, and 0 analysts rated the stock as Sell. Wells Fargo & Co reaffirmed a "sell" rating on shares of Teva Pharmaceutical Industries in a research report on Tuesday, February 13th. Finally, Leerink Swann reduced their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an "underperform" rating for the company in a research report on Friday, February 9th. ValuEngine raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, February 15th. Ten analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the company.
Comcast Corporation (CMCSA) analysts on average have given a price target of $18.73 on CMCSA stock.
Teva Pharmaceutical Industries pays an annual dividend of $0.72 per share and has a dividend yield of 3.4%. 6,085,911 shares of the company were exchanged, compared to its average volume of 20,098,131. Teva Pharmaceutical Industries Ltd has a 1 year low of $10.85 and a 1 year high of $36.19. While, the analyst predicted that the company could provide an EPS of $0.76/share. The stock has a market cap of $19,810.00, a price-to-earnings ratio of -1.14, a price-to-earnings-growth ratio of 1.73 and a beta of 0.59.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, February 8th. According to the Analysts, the Low Earnings estimate for the current quarter is $0.53, while the High earnings estimate is $0.75.Comparatively, EPS for the same quarter previous year was $1.2. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analysts' expectations of $5.29 billion. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company's stock worth $215,000 after buying an additional 5,497 shares during the last quarter.
Several analysts are forecasting growth estimate of Teva Pharmaceutical Industries Limited for the current quarter to be -36.8%.
TRADEMARK VIOLATION NOTICE: "Candriam Luxembourg S.C.A. Increases Holdings in Teva Pharmaceutical Industries Ltd (TEVA)" was posted by registrarjournal.com and is the property of of registrarjournal.com. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of USA & worldwide copyright and trademark legislation. The original version of this piece can be read at https://registrarjournal.com/2018/02/22/candriam-luxembourg-s-c-a-increases-holdings-in-teva-pharmaceutical-industries-ltd-teva.html. Relative Strength Index (RSI-14) for Teva Pharmaceutical Industries Limited (TEVA) is at 52. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines.